Indegene has announced a strategic partnership with Datavant to improve patient recruitment for clinical trials. The collaboration aims to enable faster enrollment, fewer screen failures, and more efficient processes, particularly for rare and complex studies. By integrating Datavant’s data enrichment capabilities into Indegene’s platform, the partnership seeks to streamline the identification of suitable participants and accelerate clinical research.
Strategic Collaboration Announced
September 19, 2025 marks the announcement of a strategic partnership between Indegene and Datavant. The goal is to enhance patient recruitment for clinical trials, with a particular focus on rare disease and other complex studies. This collaboration aims to leverage data to improve trial efficiency.
Key Objectives of the Partnership
The partnership between Indegene and Datavant seeks to enable faster clinical trial enrollment, reduce the number of screen failures, and create more efficient recruitment processes for biopharmaceutical organizations. Integrating Datavant’s data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform is central to achieving these goals. This allows for a better understanding of eligible patients and streamlines the identification of suitable participants for specific health data criteria. Datavant processes over 100 million patient records annually.
Expected Outcomes and Benefits
The collaboration seeks to provide more eligible participants with opportunities to connect to trials tailored for their specific health conditions. The benefits include reduced site-level screen failures, accelerated enrollment timelines, improved screen-to-randomization ratios, and more informed decision-making. This partnership will enable companies to find the patients for trial more efficiently, especially in rare diseases where finding enough patients to reach new therapies has been a long standing challenge.
Source: BSE
